Board/Management Information • Apr 16, 2019
Board/Management Information
Open in ViewerOpens in native device viewer
Paris (France), April 16, 2019, 6pm - BIOPHYTIS (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel therapeutics for age-related diseases, today announced the publication of the 2018 Annual Financial Report, which has been filed with the Autorité des Marchés Financiers (AMF). Biophytis also announced Jean-Gérard Galvez has resigned from the Board of Directors.
The Financial Report is available on Biophytis' website: http://www.biophytis.com and on AMF's website: www.amf-france.org.
Effective as of April 12, 2019, Jean-Gérard Galvez has resigned from the Board of Directors for personal reasons. Mr. Galvez has served on the Board for 10 years and no disagreement exists between the parties. The Biophytis team wishes him the best both professionally and personally.
The Board of Directors currently consists of five members, four being independent directors.
*****
Biophytis is a clinical-stage biotechnology company focused on the development of novel therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biologicalstressesthat lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is for the treatment of neuromuscular diseases, including sarcopenia andDuchenne muscular dystrophy.Oursecond drug candidate, Macuneos (BIO201), is for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit www.biophytis.com.
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are not promises or guarantees and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of the risks and uncertainties that could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please consult the Risk Factors section of the Company's registration document and other regulatory filings filed with the French Autorité des Marchés Financiers (AMF), which are available on the AMF website (www.amf-france.org) and at www.biophytis.com. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, Biophytis undertakes no obligation to update or revise the information contained in this press release. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.
Daniel Schneiderman, CFO [email protected] Tel: +1 (857) 220-9720
LifeSci Public Relations Cherilyn Cecchini, M.D. [email protected] Tel: +1 (646) 876-5196
Citigate Dewe Rogerson Laurence BAULT/Antoine DENRY [email protected] [email protected] Tel: +33 (0) 1 53 32 84 78 Mob: +33(0)6 64 12 53 61
Source: Biophytis SA
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.